SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, announced today that ongoing research and development activities of the Company’s CoPrimer™ platform technology has yielded positive results in demonstrating the capabilities of CoPrimers in multiplex tests for SNP detection.

The Company will utilize its proprietary design software and patent-pending CoPrimer technology to provide molecular testing solutions for use by customers. These include enterprise clients, specifically those interested in testing for targeted gene sequences in multiplexed reactions, in the research, infectious diseases, agricultural, ranching, and food production industries, as well as large clinical laboratories. The above industries rely upon molecular testing for a variety of applications, ranging from testing for harmful bacteria or vector-borne diseases, liquid biopsy applications, and developing in-house diagnostics to assist with infectious disease testing. Customers in the latter category would be able to use the technology to design and verify their own laboratory developed tests (“LDTs”).

Co-Diagnostics CEO Dwight Egan commented: “The unique properties of CoPrimers make them ideally suited for a variety of applications where sensitivity is the key to optimal results, including multiplexing several targets, enhanced SNP detection, and rare allele enrichment for next-gen sequencing. Co-Diagnostics is excited to provide these groundbreaking technical advances to the worldwide molecular testing market.”

About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that has developed and intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), and to sell diagnostic equipment from other manufacturers as self-contained lab systems.

Forward-Looking Statements:
This press release contains forward-looking statements. Forward-looking statements can be identified by words such as “believes,” “expects,” “estimates,” “intends,” “may,” “plans,” “will” and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

Company Contact:
Co-Diagnostics
Andrew Benson
Co-Diagnostics Investor Relations
801-438-1036
investors@codiagnostics.com
or
Investor Contact:
Lytham Partners, LLC
Joe Diaz, Robert Blum and Joe Dorame
602-889-9700
codx@lythampartners.com